Retroviral vectors
By reducing the number of ORFs in the RNA sequence of retroviral vectors and introducing codon substitution modifications, the problems of low efficiency and high safety risks of vector transduction in the airway epithelial are solved, and efficient and safe gene transduction and long-term transgene expression are achieved.
Patent Information
- Application Number
- CN202380058029.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-08-26
- Filing Date
- 2023-08-25
- Publication Date
- 2025-03-25
AI Technical Summary
Existing retroviral vectors are inefficient and at high risk of safety when transducing to the airway epithelium, especially at risk of excessive retroviral open reading frames (ORFs), which may lead to immune responses and the generation of replication-competent viruses.
A modified retroviral vector is designed with RNA sequences that reduce the number of retroviral ORFs and introduce specific codon substitution modifications, reducing the risk of immune response and improving the safety and yield of vectors.
It has achieved efficient transduction of transgene genes in airway epithelial cells, maintained long-term transgene expression, and improved vector yield and safety, avoiding the generation of replication-competent viruses.